key: cord-0808040-uh2murwm
authors: Hou, Xianliang; Fan, Wentao; Wang, Guangyu; Chen, Xiaoyan; Mo, Chune; Wang, Yongsi; Gong, Weiwei; Wen, Xuyan; Chen, Hui; He, Dan; Mo, Lijun; Jiang, Shaofeng; Ou, Minglin; Guo, Haonan; Liu, Hongbo
title: T cell receptor repertoires as potential diagnostic markers for patients with COVID-19
date: 2021-10-22
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.10.033
sha: 55ac8b1f056ea4cd21444cef32c7c119fc8f7539
doc_id: 808040
cord_uid: uh2murwm

Objective Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing global health emergency. T cell receptor (TCR) are crucial mediators of antiviral adaptive immunity. Here, we sought to comprehensively characterize the TCR repertoire changes in patients with COVID-19. Design We implemented a large sample size multi-center randomized controlled trial to study the TCR repertoire features, and identify COVID-19 disease-related TCR sequences. Results We found that some TCRβ features of COVID-19 patients were remarkably different from that of healthy control, including decreased repertoire diversity, longer CDR3 length, skewed utilization of the TRBV/J, and a high degree of TCRβ sharing. Moreover, this analysis showed TCR repertoire diversity declines with aging, which may be a cause of higher infection and mortality in elderly patients. Importantly we identified a set of TCRβ clones, which can distinguish COVID-19 patients from healthy controls with high accuracy. Notably, this diagnostic model demonstrates 100% specificity and 82.68% sensitivity at 0-3 days post diagnosis. Conclusions This study lay the foundation for immunodiagnosis and the development of medicines and vaccines for COVID-19 patients.

COVID-19, caused by SARS-CoV-2, has spread rapidly worldwide (Lai et al., 2020) .

As of June 20, 2021, SARS-CoV-2 has affected more than 179,060,045 people and killed over 3.87 million people. In the US, As many as 34,401,766 individuals have 4 tested positive for the COVID-19, and the death toll reached 617,091 people (Baidu, 2021 ). COVID-19 shows symptoms of dry cough, fever, diarrhea, fatigue, pneumonia, and conjunctivitis. Some patients develop acute respiratory distress syndrome (ARDS), severe pneumonia, or multiple organ failure (Ahn et al., 2020; Guo et al., 2020; Lai et al., 2020) . Following its global spread, the World Health Organization declared the current outbreak of coronavirus a public health emergency of global concern. Although clinicians and scientists worldwide have made great efforts to explored antiviral drugs and produce vaccines (Ahn et al., 2020; Guo et al., 2020; Lai et al., 2020) , there is still no highly effective clinical treatment and specific medicine for COVID-19. Thus, it's urgent to better understand the host immune response in SARS-CoV-2 virus infection to better devise diagnostic and prognostic biomarkers and design effective therapeutic interventions for the disease.

T cells are the central mediators of antiviral adaptive immunity and play critical roles in clearing SARS-CoV-2 infections and directly influences the clinical outcome of patients (Ahn et al., 2020; Guo et al., 2020; Lai et al., 2020) . T cell antigen recognition requires T cell receptors (TCRs), which expressed on the T cell surface.

The antigen specificity of each TCR is primarily determined by the hypervariable CDR3 of the receptor chain, which originated from the recombination of the V (variable), D (diversity), and J (joining) gene segments and the deletion and insertion of nucleotides at the V(D)J junctions . These process generates a diverse TCR repertoire capable of recognizing an extensive and unpredictable range of antigens and providing potent antiviral immunity (Hou et al., 5 2019; . The composition and the diversity of the TCR repertoire changes in response to cancer, aging, chronic and acute infection, and many other internal and external forces, making the TCR repertoire highly dynamic. Specific recognition of antigens result in clonal expansion of antigen-specific T cells, leading to skewing of the TCR repertoire (TCR bias) to favor antigen-specific T cells (Hou et al., 2016; Wen et al., 2020) . Evidence for TCR bias in antiviral immunity is demonstrated for many viral infections, such as the Epstein-Barr virus (EBV) (Gil et al., 2020) and SARS-CoV (Gutierrez et al., 2020) , and the Middle East respiratory syndrome coronavirus (MERS-CoV) (Channappanavar et al., 2014) . With the development of technology, ImmunoSEQ-technology allows ultra-deep sequencing of the TCRβ CDR3 region and reveals the composition and characterization of T cell populations (Channappanavar et al., 2014) . Relevant to this investigation, Zhang and co-workers found that COVID-19-induced remodeling of peripheral lymphocytes and SARS-CoV-2-specific shuffling of adaptive immune repertories. They also indicated that peptides derived from the M protein of SARS-CoV-2 are active in inducing T-cell response in most of the COVID-19 patients .

Here, we performed a comprehensive immunological analysis with large scale and multi-center to decode the adaptive immune response directed against the SARS-CoV-2 virus using high-throughput immune sequencing. The study comprehensively address the correlations between TCR diversity and immune responses against viral antigens, and explored that what extent SARS-CoV-2 influences the TCR repertoire, including TCR diversity, CDR3 frequency distribution, 6 CDR3 length distribution, V/J usage, V-J pairing, and overlap indices. Especially, we're trying to identify the TCRs specific for SARS-CoV-2 viral antigens in COVID-19 patients. Through our study, we hope to gain a better understanding of the adaptive immune response to SARS-CoV-2 infection, and provide a theoretical basis for the development of effective drugs or vaccines to against SARS-CoV-2.

All TCR sequences for subjects were obtained from the ImmuneRACE study (Nolan et al., 2020) . As described previously, the ImmuneRACE study is a prospective, single group, multi-cohort, exploratory study of participants infected with COVID-19 (Nolan et al., 2020) . This study includes T-cell repertoire data from 593 subjects from 3 global collaborators. Participants, aged 8 to 89 years and residing in 24 different geographic areas across the United States, were consented and enrolled via a virtual study design. All of the samples were collected from subjects who were actively suffering from, or had recovered from COVID-19. In the COVID-19-BWNW group, whole blood samples were collected at Bloodworks Northwest (Seattle, WA);

In the COVID-19-DLS group, whole blood samples were collected at Discovery Life Sciences (Huntsville, AL); In the COVID-19-HUniv12Oct group, whole blood samples were collected at the Hospital Univesitario 12 de Octubre (Madrid, Spain). In addition, the TCR sequences for healthy controls were obtained from Adaptive Biotechnologies immuneACCESS siIte (https://doi.org/10.21417/B7SG6T). Actually 7 43 healthy subjects were included in the study. Peripheral blood samples were collected from healthy donors who tested negative for anti-hepatitis B surface antigen (anti-HBsAg) antibodies and anti-HIV antibodies and exhibited no clinical or laboratory signs of other infectious diseases or immunological disorders. Among these 43 healthy donors, twenty were males and twenty-three were females, and had a mean age of 46.16 ± 15.56 years, ranging from 30 to 61 years.

Whole blood samples blood were taken from each volunteer, and collected in K2EDTA tubes. Samples were stored at the institution and sent to Adaptive as frozen whole blood, isolated Peripheral blood mononuclear cells (PBMC), and DNA extracted from either sample type for TCRβ analysis via the immunoSEQ.

Immunosequencing of the TCRβ CDR3 regions was performed using the immunoSEQ Assay as previously described (Robins et al., 2012; Carlson et al., 2013) .

In brief, a bias-controlled multiplex-PCR system was designed to amplify the extracted genomic DNA. Subsequently, high-throughput sequencing was performed.

Raw data processing and analysis were performed with the ImmunoSEQ Analyzer software (http://www.adaptivebiotech.com/immunoseq). Demultiplexed reads were then further processed to reduce amplification and sequencing bias. TCR-β V, D and J gene definitions were provided by the IMGT database (www.imgt.org). Because any given CDR3 sequence can be produced in multiple ways, the probability distribution of hidden recombination events cannot be inferred directly from the observed sequences (Elhanati et al., 2018; Pogorelyy et al., 2018) . Therefore, we used the 8 methods exist to calculate the probability of TCR nucleotide sequences from a given recombination model (Murugan et al., 2012) . The probabilistic model predicts the generation probability of any specific CDR3 sequence by the primitive recombination process, which was sufficient to allow annotation of the V(N)D(N)J genes constituting each unique CDR3 and to obtain the corresponding AA sequence.

Moreover, Batch correction was performed to eliminate the batch effect between different data sets. In addition, multiple TCR data statistics were performed, including CDR3 frequency distribution, CDR3 length distribution, V/J usage, V-J pairing, and the length distribution of Vdels, Jdels, D5dels, D3dels, n1ins, and n2ins. All of these analyses were assessed based on earlier published work (Gomez-Tourino et al., 2017; Huang et al., 2019) . TCR repertoire diversity was calculated based on the D50 index, Shannon index, Simpson index, and inversesimpson index (Stewart et al., 1997; Venturi et al., 2007) . Sharing among TCR repertoires was quantified by calculating the overlap coefficient (overlap (X, Y) = |X and Y|/min (|X|, |Y|) for amino acid sequences (species = nucleotide sequence). Besides, to further identify the COVID-19-associated clones, we searched for the clones which were highly abundant in COVID-19 group but rare in the HC group, as previously described methods (Huang et al., 2019) .

Disease associated clones were defined as those TCRβ presenting in at least four COVID-19 patients and less than three healthy individuals. Through screening, the disease-related clones were obtained. 9

We used the random forest model in R package based on two features, the proportion of unique disease associated clones presented in the sample (the number of disease associated clones divided by the total number of clones in the sample) and the proportion of total disease associated clones presented in the sample (the sum frequency of disease associated clones in the sample). Exhausted leave-one-out cross validation was used to assess the identifier's performance during model training.

Concretely, given there were N samples in each group, 4/5N samples were used as training data and processed the above classification model. The left 1/5N samples were used as testing data to perform the classification.The cross validations were repeated for 5N times until every sample was used as testing data for 5 times (Huang et al., 2019) . Receiver operating characteristic (ROC) curves and AUC values were calculated using the predicted probability of a given TCRβ chain belonging to the COVID-19 population. Accuracy was calculated as the percentage of correct predictions divided by the total number of predictions made. Subsequently, we used new independent cohort of COVID donors (n=538), health controls (n=36) and rheumatoid arthritis (n=65) patients to prove the potential use of these disease associated TCRβ clones as biomarker of SARS-CoV-2 infection.

Assessment of statistical significance was performed using Mann-Whitney U-tests or unpaired t-tests where appropriate. Statistical analyses were performed using SPSS20, and a two-tailed p-value less than 0.05 was considered significant.

We used Simpson index and Inverse-Simpson index to investigate the TCRβ diversity of the peripheral blood mononuclear cells of COVID-19 patients from Bloodworks Northwest (BWNW), Discovery Life Sciences (DLS), and Hospital Univesitario 12 de Octubre (HUniv12Oct). For Simpson index and Gini index, the smaller the index value, the greater the CDR3 diversity. For D50, Shannon, Inverse-Simpson, and True diversity indices, the greater the index value, the greater the CDR3 diversity. As shown in Figure 1 , the highest diversity was healthy control (HC) group, and a lower TCR diversity was observed in COVID-19 patients than the controls, especially in the DLS group and HUniv12Oct group. However, the differences were not always statistically significant (p<0.05), especially for the comparison between BWNW group and HC group. Also, we divided the COVID-19 patients into four groups (21-40, 41-60, 61-80, 80+) according to their age, and found that TCR repertoire diversity declines with aging ( Figure 2 ).

In the context of similar HLA molecules, antigen-driven stimulation results in oligoclonal expansion of T cells via common V-D-J segments. To study the preference genes and unique changes of TCR in COVID-19 patients, we compared the usage frequency of TRBV and TRBJ genes in COVID-19 patients with that in the HCs The results show that TRBV3, TRBV9, TRBV11, TRBV12, TRBV15,   TRBV21, TRBV24, and TRBV27, showed higher usage, while TRBV1, TRBV5,   TRBV6 , and TRBV19 showed significantly lower usage in COVID-19 patients when compared with HCs. It was worth noticing that the specific skewed usages of TRBV3, TRBV9, TRBV11, TRBV12, TRBV15, and TRBV24 could be observed in COVID-19 patients from all the three global collaborators ( Figure 3A -C). The preferred TRBJs were TRBJ1-2 and TRBJ1-6, whereas the low usage TRBJs were TRBJ1-4 and TRBJ2-6, results that were consistent in all the three global collaborators ( Figure 3D-F) . Moreover, the top three pairing frequencies in COVID-19 patients were TRBV7-TRBJ2-7, TRBV5-TRBJ2-7, and TRBV6-TRBJ2-3 ( Figure 3G -I, Figure S1 ).

TCR CDR3 loops can vary in both sequence and length, and this gives them the ability to recognize a large and diverse array of antigens. We found that CDR3 length distributions differed between COVID-19 patients and normal control, which showed a shift towards longer clonotypes in COVID-19 patients cells versus HC, no matter in BWNW, DLS, or HUniv12Oct group ( Figure 4A-C) . Long TCRβ CDR3 lengths might arise from abnormal insertions and/or deletions at the V-D-J recombinant junctions. Therefore, to understand the molecular mechanism for these features, we analyzed recombination events (indels) in each of the six rearrangement positions (Vdels, Jdels, D5dels, D3dels, n1ins, and n2ins). The results show that the length distribution of the six recombination events (indels) was obviously different between COVID-19 patients and normal control ( Figure 4D -I, Figure S2 , and Figure S3 ).

As with any other viral infection, the ability of individuals' repertoire to effectively clear SARS-CoV-2 infection is mostly dependent on its composition. To 

We are particularly interested in the appearance of SARS-CoV-2 associated T cells in the peripheral blood and the potentiality to serve as biomarkers for COVID-19 diagnosis. COVID-19 associated clones are usually abundantly and widely represented in the COVID-19 patients but rarely appear in the healthy controls. As 13 supporting evidence, we identified 15 TCRβ clones that were widely in DLS, BWNW, and HUniv12Oct group, respectively, but rare in the HC group, and the unique (irrespective of each clone' abundance) and total (including the abundance of each clone) disease-associated TCRβ clones frequencies in PBMC were significantly higher in COVID-19 patients than in healthy controls ( Figure 6A-F) . In the end, these disease-associated TCRβ clones separated COVID-19 patients from healthy controls with an accuracy of 96.76%, 97.67%, and 93.98% in DLS, BWNW, and HUniv12Oct group, respectively ( Figure 6G -I), supporting that those disease-associated TCRβ clones could be used as biomarkers for COVID-19.

Considering diagnostic strategies, when would be the best time to collect samples? To answer this question. We used the HUniv12Oct cohorts, with the COVID-19-associated TCRβ clones to evaluate whether these diagnostic strategies were more or less accurate depending on the number of days since diagnosis. Overall, the diagnostic model was highly sensitive and specific at each temporal period (Table   1 , Figure S4 ). The classifier demonstrated 100% specificity and 82.68% sensitivity at 0-3 days post diagnosis (dpd) and 94.66% specificity and 81.34% sensitivity at 4-9 dpd, further rising to 98.46% specificity and 92.3% sensitivity at 10-25 dpd. Notably, there was some reduced signal at 26-40 dpd from diagnosis (89.22% specificity and 93.84% sensitivity); subsequently, further rising to 95.38% specificity and 89.22% sensitivity at 41+ dpd. Therefore, there was highest specificity soon after diagnosis (0-3 dpd), and lowest specificity at 26-40 dpd.

In addition, we found that there is a high degree of overlap of each group's 14 fifteen disease-associated TCRβ amino acid sequences between BWNW group, DLS group, and HUniv12Oct group ( Figure 7A ). Among them, five clones were shared by three groups. After removing the repeat sequence, there were 25 unique COVID-19 associated clones among the three global collaborators. It is worth noticing that two prominent amino acid motifs (L/E-G-S-N, R/P-G-G/Q) were identified in these disease-associated clones ( Figure 7B) . Besides, the Phylogenetic tree showed that these 25 disease-associated clones are related to each other ( Figure 7C) 

COVID-19, caused by SARS-CoV-2, has recently affected over 179,060,045 people and killed more than 3.87 million people. As with any virus, the innate and adaptive immune system plays a critical role in clearing SARS-CoV-2 infections (Nussing et al., 2018; Walker 2019) , whereas a failed immune response might result in viral spreading, cytokine storm, and a high mortality rate (Nussing et al., 2018; Walker 2019 ). In the present study, we sought to comprehensively characterize the composition and the diversity of the TCR repertoire in PBMCs of COVID-19 by

ImmunoSEQ-technology. This study was a large sample size multi-center randomized controlled trial, and aimed at clustering T cells relevant for immunity against SARS-CoV-2 (Nolan et al., 2020) . It revealed that, compared to that in HCs, we found that the TCRβ diversity was obviously low in COVID-19 patients, and TCR repertoire diversity was decreased along with aging. This confirms the results from Britanova et al. They also found TCRβ diversity of naïve T cell was 60-120 million for individuals in the first two decades of life and decreased to 8-57 million in individuals over 70 years old (Britanova et al., 2016) . It may have been a contributing factor for that the mortality of young and middle-aged COVID-19 patients is lower than that of elderly patients with COVID-19 (Gutierrez et al., 2020) .

The distribution of CDR3 sequence lengths is another key feature that provides an integrative view of repertoire composition. Biases in CDR3 length are often observed in epitope-specific T cell repertoires (Pickman et al., 2013; Liu et al., 2017; Huang et al., 2019) . Indeed, we found there was a shift towards longer clonotypes in 16 COVID-19 patients versus HC. These results appear to confirm previous findings that virus-specific TCRβ clonotypes show increased TCRβ CDR3 length when compared to autoantigen-specific clonotypes (Gomez-Tourino et al., 2017) . Moreover, our experimental results showed that the length distribution of the six recombination events (indels) was obviously different between COVID-19 patients and normal control. Different rearrangements may lead to variable CDR3 lengths. TCR CDR3 loops can vary in both length and sequence, allowing for recognizing diverse Ags.

Furthermore, our analysis results showed that the TRBV/TRBJ segments' usage frequency were obvious differences between COVID-19 patients and normal control.

The skewed use of the TRBV/J segments may be associated with the immune dysfunction and the pathogenesis of the disease. In the case of disease, stimulation by SARS-CoV-2 antigens can lead to the targeted rearrangement and excessive abnormal cloning of one or a few TCR BV subfamilies, and the cloning of other T cells may be suppressed by the dominant T cell clones, which may result in impaired immune function and decreased ability to clear virus (Li et al., 2011; Sui et al., 2015) . Relevant to this investigation, Wen et al. applied single-cell RNA sequencing to characterize the changes in PBMCs from 10 COVID-19 patients. They identified an over-representation of the IGHV3 family, especially the IGHV3-21, IGHV3-7, IGHV3-30, IGHV3-15, and IGHV3-23 in COVID-19 patients compared to that in the HCs (Wen et al., 2020) . The skewed use of the TRBV/IGHV genes offers a framework for the rational design of SARS-CoV-2 vaccines.

In addition, we found that the overlap degree of TCR repertoire was significantly higher in COVID-19 patients compared with healthy control. TCRβ clonotypes that are shared between individuals are likely raised against common antigens, which are thought to play an essential role in the efficacy of pathogen-specific responses and the control of infection (Price et al., 2009; Venturi et al., 2011; Zhao et al., 2016) .

Similarly, a recent study demonstrated the presence of influenza-specific public T cells in both infected patients and healthy (Price et al., 2009; Venturi et al., 2011; Zhao et al., 2016) . Thus, if linked to certain infections, such TCRs could become invaluable tools for immunodiagnosis and vaccine development of the human disease.

Besides, we identified a set of SARS-CoV-2 associated TCRβ which can distinguish patients with COVID-19 from HC with an accuracy rate of more than 93%. Overall, our study demonstrates that the potential of disease-associated TCRβ clones as alternative biomarkers for the screening and the diagnosis of COVID-19. However, due to the limited number of samples in this analysis, validation of those biomarkers' performance and evaluating the accuracy and reliability of this method by more studies from other laboratories is needed. Moreover, we used the HUniv12Oct cohorts, with the COVID-19-associated TCRβ clones to evaluate whether these diagnostic strategies were more or less accurate depending on the number of days post diagnosis.

We found that diagnostic model was highly sensitive and specific in each temporal period, with around 95-100% specificity over the three period (0-3 dpd, 4-9 dpd, and 10-25 dpd). Relevant to this investigation, Snyder et al., (2020) In addition, it is worth noting that the potential role of cross-reactive immunity may affect the diagnostic effect. Spike (S) proteins of SARS-CoV-2 share about 97%

and 76% of amino acid identities with RaTG13 and SARS-CoV, respectively (Ou et al., 2020) . Many previous studies pointed out that there was a significant serologic cross-reactivity between SARS-CoV-2 and other coronaviruses (MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-HKU1, HCoV-229E, RaTG13, and HCoV-NL63) (Mateus et al., 2020; Hicks et al., 2021; Liu et al., 2021) and dengue virus (Lustig et al., 2020) , etc., Cross-reactivity between SARS-CoV-2 and other viruses may interfere with accurate clinical diagnosis, and lead to false-positive dengue serology among COVID-19 patients. However, another study involving a similar experimental design produced contradictory results, Ou and colleague demonstrate limited cross-neutralization between convalescent sera from SARS and COVID-19 patients (Ou et al., 2020) . In short, further research is needed to verify the accuracy of diagnosis based on TCRβ clones.

In summary, we present a comprehensive overview of TCRβ CDR3 repertoire in COVID-19 patients, including the restricted TCRβ diversity, increased CDR3 length, skewed use of the TRBV/J, and a high degree of TCRβ sharing. The most important discovery is that using our defined COVID-19-associated TCRβ clones, we can distinguish COVID-19 patients from healthy cohort. These findings demonstrate that 19 disease associated TCRβ clonotypes could work as the potential biomarker to help diagnose COVID-19, at least in screening the COVID-19.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. 

None.

This ImmuneRACE study was approved by Western Institutional Review Board 20 (WIRB reference number 1-1281891-1, Protocol ADAP-006). All participants were consented for sample collection and metadata use via electronic informed consent processes.

Abbreviations: COVID-19, Coronavirus disease 2019; SARS-CoV-2, Severe acute respiratory syndrome coronavirus; CDR3, complementarity-determining region 3;

TCR, T cell receptor; TCRβ, T cell receptor β-chains; TRBV, TCR beta chain variable gene; TRBJ, TCR beta chain joining gene.

All sequencing data have been deposited and made public in the Adaptive Biotechnologies immuneACCESS siIte (https://clients.adaptivebiotech.com/pub/ covid-2020). All other data are available from the authors upon reasonable requests. . Data are presented as the mean ± SD values, and compared using the t-test. *p < 0.05, **p < 0.01; ***p < 0.001; ****p < 0.0001 (two-tailed).

29 Figure 2 . TCR repertoire diversity declines with aging in COVID-19 patients. The COVID-19

patients are characterized into four groups (21-40, 41-60, 61-80, 80+) according to their age. The diversity is measured by the Shannon index (A), Simpson index (B), and True diversity indices (C), and Gini index (D). Data are presented as the mean ± SD values, and compared using the t-test. *p < 0.05, **p < 0.01; ***p < 0.001; ****p < 0.0001 (two-tailed).

30 (I), n2ins (J). All the CDR3 lengths, insertion (or deletion) lengths that were statistically different (p < 2×10 -4 ) between COVID-19 patients and healthy controls were presented. Data were presented as the mean ± SD values and compared using a unpaired t-test. Data were compared using a unpaired t-test, ***p < 0.001 (two-tailed).

Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)

Novel coronavirus pneumonia, Real time big data report of epidemic situation

TCR-grafted T cells restore antiviral immunity

Dynamics of Individual T Cell Repertoires: From Cord Blood to Centenarians

Using synthetic templates to design an unbiased multiplex PCR assay

T cell-mediated immune response to respiratory coronaviruses

A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy

Predicting the spectrum of TCR repertoire sharing with a data-driven model of recombination

Epstein-Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with

Convergent Recombination Drives Selection of Diverse T Cell Receptor alpha and beta Repertoires

T cell receptor beta-chains display abnormal shortening and repertoire sharing in type 1 diabetes

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

Deciphering the TCR Repertoire to Solve the COVID-19 Mystery

Next-Generation Sequencing Reveals Restriction and Clonotypic Expansion of

Treg Cells in Juvenile Idiopathic Arthritis

Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses

TCRbeta repertoire of memory T cell reveals potential role for Escherichia coli in the pathogenesis of primary biliary cholangitis

No difference in TCRbeta repertoire of CD4+ naive T 23 cell between patients with primary biliary cholangitis and healthy control subjects

Shorter TCR beta-Chains Are Highly Enriched During Thymic Selection and Antigen-Driven Selection

Current status and recent advances of next generation sequencing techniques in immunological repertoire

The landscape and diagnostic potential of T and B cell repertoire in Immunoglobulin A Nephropathy

SARS-CoV-2 vaccines in development

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Restricted TRBV repertoire in CD4+ and CD8+ T-cell subsets from CML patients

Cross-reactive memory T cells and herd immunity to SARS-CoV-2

Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species

Direct measurement of B-cell receptor repertoire's composition and variation in systemic lupus erythematosus

Potential antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Statistical inference of the generation probability of T-cell receptors from sequence repertoires

A large-scale 25 database of T-cell receptor beta (TCRbeta) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2

Innate and adaptive T cells in influenza disease

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

BCR CDR3 length distributions differ between blood and spleen and between old and young patients, and TCR distributions can be used to detect myelodysplastic syndrome

Method for identification of condition-associated public antigen receptor sequences

Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection

Ultra-sensitive detection of rare T cell clones

Single-Cell Approach to Influenza-Specific CD8(+) T Cell Receptor Repertoires Across Different Age Groups, Tissues, and Following Influenza Virus Infection

Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels

A Shannon entropy analysis of immunoglobulin and T cell receptor

Composition and variation analysis of the TCR beta-chain CDR3 repertoire in systemic lupus erythematosus using high-throughput sequencing

Methods for comparing the diversity of samples of the T cell receptor repertoire

A mechanism for TCR sharing between T cell subsets and individuals revealed by pyrosequencing

Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections

Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells

Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Preferential Use of Public TCR during Autoimmune Encephalomyelitis

Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals

A-F) The unique frequency (irrespective of each clonotype frequency) and total frequency (including the abundance of each clonotype) of disease associated TCRβ clones is significantly higher in PBMC of COVID-19 patients from BWNW group (A, D), DLS group (B, E), and HUniv12Oct group (C, F) than that in healthy controls. (G-I) The ROC curve of classification of healthy controls and COVID-19 patients from BWNW group (G), DLS group (H), and HUniv12Oct group (I) according to disease associated TCRβ clones

The overlap degree of the each group's fifteen disease associated TCRB amino acid sequences between BWNW group, DLS group, and HUniv12Oct group.The number of amino acid sequences that are unique to each group is shown in the non-overlapping sections, and the number of amino acid sequences that is common to two, and three groups is indicated in the relevant overlapping areas. (B) Two motif features are observed in the 25 non-repetition COVID-19-associated clones